Almeida Capital is pleased to be a premier sponsor of AltAssets
AltAssets HomeAlmeida Capital websiteAlmeida Capital

 

Click here for printer friendly page

European venture investment slightly weaker in Q2 03 but rate of decline slows

19/08/2003Source: AltAssets.  

Click here for the latest news, views and interviews in the clean energy investor communityEuropean venture capital investment suffered a further decline in the second quarter of this year but there were faint signs that the long-running downtrend is flattening. Both the number of transactions and the amount invested dipped slightly but the average financing size edged upwards, according to figures published by Ernst & Young and VentureOne.

European venture capitalists invested a total of E709m in Q2, a decline of 1.5 per cent from the previous quarter. The volume of investments fell by three per cent. But the average size of financing actually increased from E1.7m in the first quarter to E2m in the second, its highest level since 2001.

While Europe's overall quarterly results appear largely unchanged, trends within specific sectors point to many of the same phenomena seen recently in the US. There has been some growth in healthcare and software sectors and a sharp decline in communications and networking investment.

Commenting on the similarity between European and US investment trends, Dave Cabral, Pan-European leader of Ernst & Young's Venture Capital Advisory Group said: ‘The fact that we can see such a clear correlation in industry trends, even in a quarter when US investment rose significantly and European investment was flat, points to the truly global nature of venture capital.'

‘Investors share similar views when it comes to the potential of the healthcare and software industries, and that potential stems from the shared problems society is looking to solve today.'

Cabral went on to point out that the emphasis on healthcare is a trend that is gaining momentum and overshadowing all areas of information technology except software, which has maintained strength throughout the economic downturn. ‘Together, biopharmaceuticals and medical devices deals constitute 27 per cent of European deal flow in the second quarter. This is unprecedented.'

Steve Harmston, VentureOne's director of European research believes that Europe may finally have hit the bottom and anticipates some improvement in the second half of the year. ‘After a long period of decline, the European market stabilised in the second quarter. Historically, the European venture market has lagged the US slightly in its reaction to favourable news in the general economic and financial environment.'

‘Given this, I expect the European venture market to build on its second quarter stability and follow the lead of the US with an upturn in activity in the second half of the year,' Harmston concluded.

Copyright © 2003 AltAssets

 

 

 

top of the page

  Advanced Search

HOME | ABOUT US | CONTRIBUTE | FAQ | ADVERTISING | RSS FEED | WEEKLY NEWSLETTER SIGN-UP | CONTACT US

All rights reserved. This document and its content are for your personal, non-commercial use only. No further copying, reproduction, distribution, transmission, display of AltAssets content is allowed. To obtain permission please contact editorial@altassets.com. You may not alter or remove the copyright or any other statements from copies of the content.

AltAssets is a service offered by Almeida Capital's Research Division. Available online at www.AltAssets.net
Almeida Capital Ltd is regulated by FSA and registered in England (no. 3945728). Registered Office: Acre House, 11-15 William Road, London NW1 3ER. Legals & Terms of Use
Content is © AltAssets 2000-2008

Subscribe to our newsletter Subscribe to our newsletter Recent news itemsNews archive